Senior Project Toxicologist – Biologics
Enregistrez cette offre et organisez votre recherche
Créez un compte gratuit pour enregistrer des offres d'emploi, créer des alertes et revenir à cette liste depuis votre tableau de bord.
En continuant, vous acceptez nos Conditions d’utilisation & Politique de confidentialité.
argenx in Ghent, Belgium, seeks an experienced Project Toxicologist to steer nonclinical safety strategy across multiple modalities, with emphasis on large molecules. You will lead cross-functional teams, design safety programs, and coordinate outsourced studies with CROs, ensuring alignment with Health Authority expectations.
The role is on-site 2–3 days per week with the option to work remotely from Belgium.
-
Project Toxicologist
Il y a 15 heures
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx Temps plein 80 000 € - 110 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...
-
Senior Nonclinical Toxicology Project Lead
Il y a 5 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx SE Temps plein 80 000 € - 110 000 € Contratargenx SE is seeking an experienced Project Toxicologist to lead nonclinical safety strategies for multiple modalities, including large molecules. Based in Belgium with on-site presence, you will shape safety packages, coordinate CROs, and ensure regulatory readiness while collaborating across PharmTox and clinical teams.The role requires a PhD in...
-
Project Toxicologist
Il y a 5 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx SE Temps plein 80 000 € - 110 000 € ContratAbout the roleJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the...